Senti Biosciences, Inc. (NASDAQ:SNTI – Get Free Report) shares rose 5.2% on Thursday . The stock traded as high as $2.83 and last traded at $2.71. Approximately 11,003 shares were traded during trading, a decline of 96% from the average daily volume of 294,211 shares. The stock had previously closed at $2.58.
Senti Biosciences Price Performance
The firm has a market cap of $124.00 million, a PE ratio of -1.88 and a beta of 2.74. The business’s fifty day moving average is $2.60 and its 200-day moving average is $3.24.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Senti Biosciences stock. 8VC GP I LLC acquired a new stake in Senti Biosciences, Inc. (NASDAQ:SNTI – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 2,537,558 shares of the company’s stock, valued at approximately $1,675,000. Senti Biosciences accounts for 1.7% of 8VC GP I LLC’s portfolio, making the stock its 2nd largest holding. 8VC GP I LLC owned 5.70% of Senti Biosciences as of its most recent SEC filing. 25.73% of the stock is currently owned by hedge funds and other institutional investors.
Senti Biosciences Company Profile
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Further Reading
- Five stocks we like better than Senti Biosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- How to Use Stock Screeners to Find Stocks
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- What Are Dividend Champions? How to Invest in the Champions
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.